DNA damage induces p53-independent apoptosis through ribosome stalling.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
17 May 2024
Historique:
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 16 5 2024
Statut: ppublish

Résumé

In response to excessive DNA damage, human cells can activate p53 to induce apoptosis. Cells lacking p53 can still undergo apoptosis upon DNA damage, yet the responsible pathways are unknown. We observed that p53-independent apoptosis in response to DNA damage coincided with translation inhibition, which was characterized by ribosome stalling on rare leucine-encoding UUA codons and globally curtailed translation initiation. A genetic screen identified the transfer RNAse SLFN11 and the kinase GCN2 as factors required for UUA stalling and global translation inhibition, respectively. Stalled ribosomes activated a ribotoxic stress signal conveyed by the ribosome sensor ZAKα to the apoptosis machinery. These results provide an explanation for the frequent inactivation of SLFN11 in chemotherapy-unresponsive tumors and highlight ribosome stalling as a signaling event affecting cell fate in response to DNA damage.

Identifiants

pubmed: 38753784
doi: 10.1126/science.adh7950
doi:

Substances chimiques

AATF protein, human 0
TP53 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

785-792

Auteurs

Nicolaas J Boon (NJ)

Oncode Institute, Utrecht, Netherlands.
Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.

Rafaela A Oliveira (RA)

Oncode Institute, Utrecht, Netherlands.
Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.

Pierré-René Körner (PR)

Oncode Institute, Utrecht, Netherlands.
Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, Netherlands.

Adva Kochavi (A)

Oncode Institute, Utrecht, Netherlands.
Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, Netherlands.

Sander Mertens (S)

Oncode Institute, Utrecht, Netherlands.
Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.

Yuval Malka (Y)

Oncode Institute, Utrecht, Netherlands.
Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, Netherlands.

Rhianne Voogd (R)

Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.

Suzanne E M van der Horst (SEM)

Oncode Institute, Utrecht, Netherlands.
Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.

Maarten A Huismans (MA)

Oncode Institute, Utrecht, Netherlands.
Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.

Lidwien P Smabers (LP)

Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Jonne M Draper (JM)

Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.

Lodewyk F A Wessels (LFA)

Oncode Institute, Utrecht, Netherlands.
Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.

Peter Haahr (P)

Oncode Institute, Utrecht, Netherlands.
Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.
Center for Gene Expression, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Jeanine M L Roodhart (JML)

Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Ton N M Schumacher (TNM)

Oncode Institute, Utrecht, Netherlands.
Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.

Hugo J Snippert (HJ)

Oncode Institute, Utrecht, Netherlands.
Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, Netherlands.

Reuven Agami (R)

Oncode Institute, Utrecht, Netherlands.
Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, Netherlands.

Thijn R Brummelkamp (TR)

Oncode Institute, Utrecht, Netherlands.
Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH